TNBC is the most immunogenic subtype of breast cancer with higher levels of PD-L1 expression and tumor-infiltrating lymphocytes than other subtypes, suggesting that it is more likely to benefit from treatment with immune checkpoint inhibitors [9]. This evidence concerns the gene CD274 and neoplasm.